10x Genomics (NASDAQ:TXG) Given New $18.00 Price Target at Stifel Nicolaus
Genomics (NASDAQ:TXG – Get Free Report) had its price objective reduced by equities researchers at Stifel Nicolaus from ...
Life Science Company 10x Genomics Struggles With Profitability, Analyst Says 2025 Guidance Bakes In NIH Funding Uncertainties
On Wednesday, 10x Genomics Inc (NASDAQ:TXG) reported a fourth-quarter EPS loss of $(0.40), missing the consensus estimate of ...
GEN16d
After a Year of Launches, 10x Refocuses on Customer Support, Biopharma Market Growth
CEO Serge Saxonov, PhD, says provider of single cell, spatial, and in situ instruments expects to see benefits from sales reorganization and grow base of industry users.
Seeking Alpha24d
TXG 10x Genomics, Inc.
10x Genomics, Inc., a life science technology ... The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other ...
10x Genomics Inc (TXG) Q4 2024 Earnings Call Highlights: Navigating Challenges with Strategic ...
Despite a challenging macro environment, 10x Genomics Inc (TXG) focuses on product innovation and biopharma expansion to ...
TMCnet9d
Chan Zuckerberg Initiative Launches Billion Cells Project with 10x Genomics and Ultima Genomics to Advance AI in Biology
Today, the Chan Zuckerberg Initiative (CZI) launched the Billion Cells Project, an effort to generate an unprecedented one ...
10x Genomics: Q4 Earnings Snapshot
PLEASANTON, Calif. (AP) — PLEASANTON, Calif. (AP) — 10x Genomics Inc. (TXG) on Wednesday reported a loss of $49 million in its fourth quarter. The Pleasanton, California-based company said it had a ...
ETF Daily News25d
10x Genomics’ (TXG) Sell (E+) Rating Reiterated at Weiss Ratings
and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Receive News & Ratings for 10x Genomics Daily - Enter your email address below to ...